Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.57 |
| ▸ | APLNR | P35414 | 1/20 | 0.56 |
| ▸ | EPHA2 | P29317 | 5/20 | 0.56 |
| ▸ | CTSL | P07711 | 3/20 | 0.56 |
| ▸ | CTSS | P25774 | 3/20 | 0.56 |
| ▸ | CTSK | P43235 | 3/20 | 0.56 |
| ▸ | CTSH | P09668 | 1/20 | 0.56 |
| ▸ | F2 | P00734 | 2/20 | 0.53 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29575211 | 0.97 | EPHA2 (0.55) | OPRM1OPRK1APLNREPHA2CTSL | |
| SCHEMBL31040681 | 0.95 | EPHA2 (0.56) | OPRM1OPRK1APLNREPHA2CTSL | |
| SCHEMBL30973967 | 0.92 | CTSL (0.57) | OPRM1OPRK1APLNREPHA2CTSL | |
| SCHEMBL30526217 | 0.91 | F2 (0.62) | F2 | |
| SCHEMBL30457594 | 0.90 | APLNR (0.59) | OPRM1OPRK1APLNR | |
| SCHEMBL30948380 | 0.90 | APLNR (0.52) | OPRM1OPRK1APLNREPHA2CTSL | |
| SCHEMBL30974054 | 0.90 | CALCRL (0.56) | APLNREPHA2CTSLCTSSCTSK | |
| SCHEMBL30458060 | 0.88 | APLNR (0.62) | OPRM1OPRK1APLNRCTSLCTSS | |
| SCHEMBL29697039 | 0.88 | EPHA2 (0.58) | APLNREPHA2F2CXCR4 | |
| SCHEMBL29641118 | 0.88 | C5AR1 (0.60) | OPRM1APLNREPHA2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144842-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TRYPTOPHAN AND PHYLLOKININ DERIVATIVE FOR USE IN TREATING PSYCHIATRIC AND PSYCHOLOGICAL CONDITIONS | TEMPLE OTORONGO LLC (US) | 2026-05-28 | — | — | US | claimed |
| US-11723945-B2 | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions | TEMPLE OTORONGO LLC (US) | 2023-08-15 | — | — | US | claimed |
| US-20260144842-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TRYPTOPHAN AND PHYLLOKININ DERIVATIVE FOR USE IN TREATING PSYCHIATRIC AND PSYCHOLOGICAL CONDITIONS | TEMPLE OTORONGO LLC (US) | 2026-05-28 | — | — | US | disclosed |
| US-11723945-B2 | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions | TEMPLE OTORONGO LLC (US) | 2023-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144842-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TRYPTOPHAN AND PHYLLOKININ DERIVATIVE FOR USE IN TREATING PSYCHIATRIC AND PSYCHOLOGICAL CONDITIONS | OPRK1, TPH1, HTR3C | OPRM1 36/4885OPRK1 1/4885APLNR 732/4885 |
| US-11723945-B2 | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions | TPH1, TPH2, SYMPK | OPRM1 634/4885OPRK1 5/4885APLNR 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.